Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

@article{Aapro2008EffectOO,
  title={Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.},
  author={Matti S. Aapro and Robert C. F. Leonard and Agust{\'i} Barnadas and Maurizio Marangolo and Michael Untch and Nikolaos Malamos and Jose Maria Lalueza Mayordomo and Dietmar Reichert and Jos{\'e} Luiz Pedrini and Lidia Ukarma and Armin Scherhag and H. Burger},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 4},
  pages={592-8}
}
PURPOSE The Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS BRAVE was an open-label, randomized, multicenter study in patients with MBC treated with anthracycline- and/or taxane-based chemotherapy. Patients (hemoglobin [Hb] < 12.9 g/dL) were randomly assigned (1:1) to epoetin beta 30,000 U subcutaneously once weekly or control for 24 weeks. The primary… CONTINUE READING
45 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

Similar Papers

Loading similar papers…